The "wishful thinking" of the national development and Reform Commission makes the price of drugs difficult to implement

Source: great wisdom ashdak news agency, Nov 26, 2014, national development and Reform Commission, yesterday to China Association of chemical and pharmaceutical industry, China Association of traditional Chinese medicine, etc Three industry associations issued the proposal for promoting drug price reform (Draft for comments), which aims to simplify administration and delegate power, cancel drug government pricing, and form the actual transaction price of drugs through market competition through medical insurance fee control and bidding procurement At present, the development and Reform Commission is wishful thinking, and only suggestions are thrown out without solutions, a senior person who has long been concerned about drug bidding policy told big smart news agency "This solution must be taken together by health care and medical insurance At present, it is still difficult to implement." An insider from Zhejiang health and Family Planning Commission said that the idea of controlling drug prices with medical insurance was right, but he did not know how the effect would be, and no good plan had been put forward According to the above-mentioned consultation, the national development and Reform Commission mainly discussed the reform of drug price formation mechanism, the regulatory measures after the elimination of government pricing and the analysis of policy impact assessment According to the solicitation opinions, from January 1, 2015, to cancel the maximum retail price limit or ex factory price set by the original government, we should strengthen the supervision from four aspects: improving the drug purchase mechanism, strengthening the role of medical insurance in charge control, strengthening the supervision of medical behavior, and strengthening the supervision of price behavior, so as to keep the drug market price at a reasonable level under the guidance of medical insurance payment standard The part of drug price liberalization is undoubtedly the focus of the market According to the head of a pharmaceutical company in Jiangsu Province, the starting point of the current reform is to simplify administration and delegate power to the drug price department of the national development and Reform Commission, which powers should be retained and which should be given up This time, the national development and Reform Commission suggested that it should reserve the right to set the price of ephedrine and continue to be responsible for low-cost drugs "Prices of psychotropic substances and narcotics will not be abolished; for low-cost drugs, the NDRC will continue to dominate policy-making (such as directory selection and cost ceiling)." While others are all liberalized, that is, the drugs paid by the medical insurance fund are dominated by the medical insurance department; the prices of patent drugs, exclusive drugs and other drugs are formed through multi-party negotiations; the blood products outside the medical insurance catalog, the preventive immune drugs and contraceptives purchased by the state in a unified way, the market transaction prices are formed through bidding or negotiation According to the price comparison rules, the former national development and Reform Commission divided drug prices into three quality levels: single pricing or high quality and good price, GMP price, and non GMP price (with GMP compulsory certification, it was later cancelled) It is speculated that the prices previously set by the national development and Reform Commission will be referred to In this consultation, the national development and Reform Commission proposes to abolish the original prices, that is, the future pricing by quality level will no longer be recognized and protected (such as separate pricing and high-quality and good price), and the bidding rules may be reset accordingly He further said that this will drive the price reduction of imported drugs, individually priced drugs and high-quality and high-priced Chinese patent drugs, which will be the mainstream of price reduction in the future; in the context of multi department joint forced price reduction, patent drugs and exclusive drugs will also be the disaster area of price reduction For blood products, price liberalization is a clear advantage It is worth mentioning that the person in charge also said that after the national development and Reform Commission no longer sets the price, the medical insurance fee control and vague second bargaining suggested by the national development and Reform Commission are the supporting measures of the medical reform, and regulate the reasonable diagnosis and treatment behavior of medical institutions, which are also the main contents of the medical reform The centralized procurement by the health and Family Planning Commission and the medical insurance payment price negotiation led by the social security bureau are not the national development and Reform Commission The scope of authority and how to implement it also depends on the solution.